• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 1-A/A filed by Sharps Technology Inc.

    11/18/24 5:29:21 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    schemaVersion:
    Form 1-A Issuer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 1-A
    REGULATION A OFFERING STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    OMB APPROVAL


    FORM 1-A

    OMB Number:  3235-0286


    Estimated average burden hours per response: 608.0

    1-A: Filer Information

    Issuer CIK
    0001737995 
    Issuer CCC
    XXXXXXXX 
    DOS File Number
     
    Offering File Number
    024-12438 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Would you like a Return Copy? Checkbox checked
    Notify via Filing Website only? Checkbox not checked
    Since Last Filing? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     

    1-A: Item 1. Issuer Information

    Issuer Infomation

    Exact name of issuer as specified in the issuer's charter

    Sharps Technology Inc. 

    Jurisdiction of Incorporation / Organization

    NEVADA  

    Year of Incorporation

    2017 

    CIK

    0001737995 

    Primary Standard Industrial Classification Code

    SURGICAL & MEDICAL INSTRUMENTS & APPARATUS 

    I.R.S. Employer Identification Number

    82-3751728 

    Total number of full-time employees

    56 

    Total number of part-time employees

    0 

    Contact Infomation

    Address of Principal Executive Offices

    Address 1

    105 MAXESS ROAD 

    Address 2

    STE. 124 

    City

    MELVILLE 

    State/Country

    NEW YORK  

    Mailing Zip/ Postal Code

    11747 

    Phone

    516-445-1396 

    Provide the following information for the person the Securities and Exchange Commission's staff should call in connection with any pre-qualification review of the offering statement.

    Name

    Arthur Marcus, Esq. 

    Address 1

     

    Address 2

     

    City

     

    State/Country

     

    Mailing Zip/ Postal Code

     

    Phone

     

    Provide up to two e-mail addresses to which the Securities and Exchange Commission's staff may send any comment letters relating to the offering statement. After qualification of the offering statement, such e-mail addresses are not required to remain active.

    Financial Statements

    Use the financial statements for the most recent period contained in this offering statement to provide the following information about the issuer. The following table does not include all of the line items from the financial statements. Long Term Debt would include notes payable, bonds, mortgages, and similar obligations. To determine "Total Revenues" for all companies selecting "Other" for their industry group, refer to Article 5-03(b)(1) of Regulation S-X. For companies selecting "Insurance", refer to Article 7-04 of Regulation S-X for calculation of "Total Revenues" and paragraphs 5 and 7 of Article 7-04 for "Costs and Expenses Applicable to Revenues".

    Industry Group (select one) Radio button not checked Banking Radio button not checked Insurance Radio button checked Other

    Balance Sheet Information

    Cash and Cash Equivalents

    $ 2473197.00 

    Investment Securities
    $ 0.00 
    Total Investments

    $  

    Accounts and Notes Receivable

    $ 2547106.00 

    Loans

    $  

    Property, Plant and Equipment (PP&E):

    $ 6233595.00 

    Property and Equipment

    $  

    Total Assets

    $ 11253898.00 

    Accounts Payable and Accrued Liabilities

    $ 1224951.00 

    Policy Liabilities and Accruals

    $  

    Deposits

    $  

    Long Term Debt

    $ 162000.00 

    Total Liabilities

    $ 4748195.00 

    Total Stockholders' Equity

    $ 6505703.00 

    Total Liabilities and Equity

    $ 11253898.00 

    Statement of Comprehensive Income Information

    Total Revenues

    $ 0.00 

    Total Interest Income

    $  

    Costs and Expenses Applicable to Revenues

    $ -5780362.00 

    Total Interest Expenses

    $  

    Depreciation and Amortization

    $ 0.00 

    Net Income

    $ -4769774.00 

    Earnings Per Share - Basic

    $ -4.53 

    Earnings Per Share - Diluted

    $ -4.53 

    Name of Auditor (if any)

    PKF O' Connor Davies, LLP 

    Outstanding Securities

    Common Equity

    Name of Class (if any) Common Equity

    Common Stock 

    Common Equity Units Outstanding

    1797795 

    Common Equity CUSIP (if any):

    82003F200 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    The Nasdaq Stock Market LLC 

    Preferred Equity

    Preferred Equity Name of Class (if any)

    Series A Preferred 

    Preferred Equity Units Outstanding

    0 

    Preferred Equity CUSIP (if any)

    000000000 

    Preferred Equity Name of Trading Center or Quotation Medium (if any)

    N/A 

    Debt Securities

    Debt Securities Name of Class (if any)

    N/A 

    Debt Securities Units Outstanding

    0 

    Debt Securities CUSIP (if any):

    000000000 

    Debt Securities Name of Trading Center or Quotation Medium (if any)

    N/A 

    1-A: Item 2. Issuer Eligibility

    Issuer Eligibility

    Check this box to certify that all of the following statements are true for the issuer(s)

    Checkbox checked

    • Organized under the laws of the United States or Canada, or any State, Province, Territory or possession thereof, or the District of Columbia.
    • Principal place of business is in the United States or Canada.
    • Not subject to section 13 or 15(d) of the Securities Exchange Act of 1934.
    • Not a development stage company that either (a) has no specific business plan or purpose, or (b) has indicated that its business plan is to merge with an unidentified company or companies.
    • Not an investment company registered or required to be registered under the Investment Company Act of 1940.
    • Not issuing fractional undivided interests in oil or gas rights, or a similar interest in other mineral rights.
    • Not issuing asset-backed securities as defined in Item 1101 (c) of Regulation AB.
    • Not, and has not been, subject to any order of the Commission entered pursuant to Section 12(j) of the Exchange Act (15 U.S.C. 78l(j)) within five years before the filing of this offering statement.
    • Has filed with the Commission all the reports it was required to file, if any, pursuant to Rule 257 during the two years immediately before the filing of the offering statement (or for such shorter period that the issuer was required to file such reports).

    1-A: Item 3. Application of Rule 262

    Application Rule 262

    Check this box to certify that, as of the time of this filing, each person described in Rule 262 of Regulation A is either not disqualified under that rule or is disqualified but has received a waiver of such disqualification.

    Checkbox checked

    Check this box if "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement.

    Checkbox not checked

    1-A: Item 4. Summary Information Regarding the Offering and Other Current or Proposed Offerings

    Summary Infomation

    Check the appropriate box to indicate whether you are conducting a Tier 1 or Tier 2 offering Radio button not checked Tier1 Radio button checked Tier2
    Check the appropriate box to indicate whether the financial statements have been audited Radio button not checked Unaudited Radio button checked Audited
    Types of Securities Offered in this Offering Statement (select all that apply)
    Checkbox checkedEquity (common or preferred stock) 
    Does the issuer intend to offer the securities on a delayed or continuous basis pursuant to Rule 251(d)(3)? Radio button checked Yes Radio button not checked No
    Does the issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
    Does the issuer intend to price this offering after qualification pursuant to Rule 253(b)? Radio button checked Yes Radio button not checked No
    Will the issuer be conducting a best efforts offering? Radio button checked Yes Radio button not checked No
    Has the issuer used solicitation of interest communications in connection with the proposed offering? Radio button not checked Yes Radio button checked No
    Does the proposed offering involve the resale of securities by affiliates of the issuer? Radio button not checked Yes Radio button checked No
    Number of securities offered
    1945591 
    Number of securities of that class outstanding
    1797795 

    The information called for by this item below may be omitted if undetermined at the time of filing or submission, except that if a price range has been included in the offering statement, the midpoint of that range must be used to respond. Please refer to Rule 251(a) for the definition of "aggregate offering price" or "aggregate sales" as used in this item. Please leave the field blank if undetermined at this time and include a zero if a particular item is not applicable to the offering.

    Price per security
    $ 3.6000 
    The portion of the aggregate offering price attributable to securities being offered on behalf of the issuer
    $ 7004127.00 
    The portion of the aggregate offering price attributable to securities being offered on behalf of selling securityholders
    $ 0.00 
    The portion of the aggregate offering price attributable to all the securities of the issuer sold pursuant to a qualified offering statement within the 12 months before the qualification of this offering statement
    $ 0.00 
    The estimated portion of aggregate sales attributable to securities that may be sold pursuant to any other qualified offering statement concurrently with securities being sold under this offering statement
    $ 0.00 
    Total (the sum of the aggregate offering price and aggregate sales in the four preceding paragraphs)
    $ 7004127.00 

    Anticipated fees in connection with this offering and names of service providers

    Underwriters - Name of Service Provider
    N/A
    Underwriters - Fees
    $ 0.00 
    Sales Commissions - Name of Service Provider
    Aegis Capital
    Sales Commissions - Fee
    $ 560330.00 
    Finders' Fees - Name of Service Provider
    N/A
    Finders' Fees - Fees
    $ 0.00 
    Accounting or Audit - Name of Service Provider
    Accountants
    Accounting or Audit - Fees
    $ 20000.00 
    Legal - Name of Service Provider
    Sichenzia Ross Ference Carmel LLP
    Legal - Fees
    $ 80000.00 
    Promoters - Name of Service Provider
    N/A
    Promoters - Fees
    $ 0.00 
    Blue Sky Compliance - Name of Service Provider
    N/A
    Blue Sky Compliance - Fees
    $ 0.00 
    CRD Number of any broker or dealer listed:
    000015007 
    Estimated net proceeds to the issuer
    $ 6343797.00 
    Clarification of responses (if necessary)
     

    1-A: Item 5. Jurisdictions in Which Securities are to be Offered

    Jurisdictions in Which Securities are to be Offered

    Using the list below, select the jurisdictions in which the issuer intends to offer the securities

    Selected States and Jurisdictions

    NEVADA

    Using the list below, select the jurisdictions in which the securities are to be offered by underwriters, dealers or sales persons or check the appropriate box

    None Checkbox not checked
    Same as the jurisdictions in which the issuer intends to offer the securities Checkbox checked
    Selected States and Jurisdictions

    NEVADA

    1-A: Item 6. Unregistered Securities Issued or Sold Within One Year

    Unregistered Securities Issued or Sold Within One Year

    None Checkbox not checked

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Sharps Technology, Inc. 
    (b)(1) Title of securities issued
    Common Stock and Accompanying Warrants
     
    (2) Total Amount of such securities issued
    449864
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $1,594,860.00
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Act

    (d) Indicate the section of the Securities Act or Commission rule or regulation relied upon for exemption from the registration requirements of such Act and state briefly the facts relied upon for such exemption
    These securities were sold in reliance upon the exemption provided by Section 4(a)(2) of the Securities Act for transactions not involving a public offering.
     
    Get the next $STSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Saba Capital Management, L.P. sold $86,371 worth of shares (37,182 units at $2.32) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/20/26 5:55:14 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Large owner Saba Capital Management, L.P. sold $240,010 worth of shares (107,465 units at $2.23) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/15/26 12:48:07 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Saba Capital Management, L.P. claimed ownership of 1,656,635 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    1/15/26 12:33:16 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    SEC Filings

    View All

    SEC Form EFFECT filed by Sharps Technology Inc.

    EFFECT - Sharps Technology Inc. (0001737995) (Filer)

    2/2/26 12:15:19 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.

    SCHEDULE 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    1/23/26 6:09:54 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Sharps Technology Inc. (0001737995) (Filer)

    1/16/26 4:30:44 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sharps Technology and BitGo Announce Collaboration to Advance Solana Treasury Strategy

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association ("BitGo"), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo's services. As part of this arrangement, STSS intends to utilize BitGo's institutional-grade qualified custody through its OCC regulated entity, BitGo Bank & Trust, National Association. In addition, STSS intends to leverage BitGo's Solana staking validator to earn com

    2/5/26 7:00:00 AM ET
    $BTGO
    $STSS
    Finance: Consumer Services
    Finance
    Medical/Dental Instruments
    Health Care

    Sharps Technology Reports Strong Solana Staking Income

    NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company"), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights. Treasury Updates Staking: Since inception, STSS's validator partners have generated ~7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company's SOL holdings are currently staked.Balance Sheet: STSS continues to maintain sufficient operating capital and has no corporate debt. Recent Operational Highlights In January, STSS announced a lock-up agreement with its Strategic Advi

    1/26/26 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions. In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in Placement

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples

    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

    NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

    2/16/24 2:42:54 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

    Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

    7/12/23 8:33:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Justin Page as Vice President of Technical Operations

    NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

    2/9/23 9:21:23 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Financials

    Live finance-specific insights

    View All

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

    6/7/24 9:00:00 AM ET
    $SNGX
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

    9/29/23 9:00:00 AM ET
    $AREC
    $RVPH
    $STSS
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care